Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear enzyme and the founding member of the PARP family of enzymes. Inhibition of PARP-1 has been the focus of drug discovery groups for over three decades in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, inflammation, diabetes and most importantly cancer. Despite the great therapeutic potential for this target and over a decade of clinical studies, only recently have PARP inhibitors made headway in late stage clinical trials. After many tribulations, recent results from several PARP inhibitors in Phase II clinical trials for cancer therapy have reinvigorated the field. This chapter is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target for oncology and explain the genesis of the PARP inhibitor pharmacophore. In addition, this chapter will provide the optimization paradigms for each of the PARP inhibitors currently in clinical trials, analyzing some of the differentiating factors for the clinical compounds and a brief mention of the current clinical progress for each inhibitor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yelamos J, Schreiber V, Dantzer F (2008) Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 14:169
Langelier MF, Planck JL, Roy S, Pascal JM (2012) Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336:728
Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283:593
De Vos M, Schreiber V, Dantzer F (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 84:137
Ogata N, Ueda K, Kagamiyama H, Hayaishi O (1980,) ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites. J Biol Chem 255:7616
Caldecott KW (2003) XRCC1 and DNA strand break repair. DNA Repair 2:955
Audebert M, Salles B, Calsou P (2004) Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 279:55117
Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517
La Thangue NB, Kerr DJ (2011) Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8:587
Murai J et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588
Clark JB, Ferris GM, Pinder S (1971) Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5’-methyl nicotinamide. Biochim Biophys Acta 238:82
Purnell MR, Whish WJ (1980) Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 185:775
Banasik M, Komura H, Shimoyama M, Ueda K (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569
Levi V, Jacobson EL, Jacobson MK (1978) Inhibition of poly(ADP-ribose) polymerase by methylated xanthines and cytokinins. FEBS Lett 88:144
Shall S (1975) Proceedings: experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. J Biochem 77:2p
Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM, Sebolt-Leopold JS (1991) Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anti-Cancer Drug Des 6:107
Ferraris D et al (2003) Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J Med Chem 46:3138
Griffin RJ et al (1998) Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem 41:5247
Ferraris DV (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53:4561
Griffin RJ et al (1995) Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anti-Cancer Drug Des 10:507
Ruf A, de Murcia G, Schulz GE (1998) Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 37:3893
Skalitzky DJ et al (2003) Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 46:210
Tao M et al (2006) Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett 16:938
Zhang WT et al (2009) Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 52:718
Gangloff AR et al (2013) Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors. Bioorg Med Chem Lett 23:4501
Ferrigno F et al (2010) Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells. Bioorg Med Chem Lett 20:1100
Wahlberg E et al (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30:283
Bregman H et al (2013) Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. J Med Chem 56:4320
Shultz MD et al (2013) Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. J Med Chem 56:7049
White AW et al (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem 43:4084
Canan Koch SS et al (2002) Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 45:4961
White AW et al (2004) Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 14:2433
Tikhe JG et al (2004) Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem 47:5467
Thomas HD et al (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 6:945
Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134:649
Plummer R et al (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917
Sleijfer S, Bogaerts J, Siu LL (2013) Designing transformative clinical trials in the cancer genome era. J Clin Oncol 31:1834
Penning TD et al (2008) Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorg Med Chem 16:6965
Penning TD et al (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514
Donawho CK et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728
Rugo HS et al (2013) In 36th Annual San Antonio Breast Cancer Symposium. (San Antonio, TX), vol. Abstract S5–02
Jones P et al (2009) Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 52:7170
Sandhu SK et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882
Michie CO et al (2013) Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC). J Clin Oncol 31:2513 (Meeting Abstracts)
Menear KA et al (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51:6581
Cockcroft XL et al (2006) Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 16:1040
Loh VM, Jr. et al (2005) Phthalazinones. Part 1: the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorganic Med Chem Lett 15:2235
Fong PC et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 361:123
Khan OA et al (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104:750
Audeh MW et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245
Edwards SL et al (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111
Jaspers JE et al (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3:68
Wang BSJ, (CA, US), Chu, Daniel (Santa Clara, CA, US), Liu, Yongbo (Shanghai, CN), Jiang, Quan (Shanghai, CN), Lu, Lei (Zhejiang Province, CN). (United States, 2011). The international patent publication number is WO 2011/097602 A1
Wang B et al (2011) In Proceedings of the AACR-NCI-EORTC International Conference, San Francisco, CA. (Mol Cancer Ther), vol 10 (11 Suppl) Abstract B64
Shen Y et al (2013) BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19:5003
Murai J et al (2014) Stereospecific PARP Trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433–443
De Bono JS et al (2013) ASCO 31(suppl abstr 2580) (J Clin Oncol, 2013)
Zhang J (1999) PARP inhibition: a novel approach to treat ischemia/reperfusion and inflammation-related injuries. Exp Opin Emerg Drugs 4:209
Zhang J et al (2000) GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 278:590
Mita AC et al (2011) In AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. (Mol Cancer Ther, San Francisco, CA), vol 10 (11 Suppl) Abstract B185
McGonigle S et al (2012) In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. (Cancer Res, Chicago, IL), vol 72 (8 Suppl) Abstract 4688
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ferraris, D. (2015). Overview of PARP Inhibitor Design and Optimization. In: Curtin, N., Sharma, R. (eds) PARP Inhibitors for Cancer Therapy. Cancer Drug Discovery and Development, vol 83. Humana Press, Cham. https://doi.org/10.1007/978-3-319-14151-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-14151-0_7
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-14150-3
Online ISBN: 978-3-319-14151-0
eBook Packages: MedicineMedicine (R0)